– Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of differentiation syndrome – – First patient dosed in.
Syndax Pharmaceuticals (SNDX) Reports Updates and Anticipated 2024 Milestones streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Syndax Highlights Recent Updates and Anticipated 2024 Milestones kptv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kptv.com Daily Mail and Mail on Sunday newspapers.
– NDA submission initiated for revumenib in R/R KMT2Ar acute leukemia under RTOR – – mNPM1 final efficacy data from the Phase 1 portion of AUGMENT-101.